Europe market is also expected to witness rapid growth over the forecast period. This is due to
expected launch of major products in the market over the forecast period. Europe-based leading
generic manufacturers such as Sandoz (a Novartis International AG’s division) and Mylan N.V.
has shown interest in this field. Mylan N.V. has entered into a collaboration agreement with
Biocon Limited to develop biosimilars in 2009. The duo got approval for their first biosimilar
product in 2017 in U.S. and also, European Medicines Agency (EMA) has accepted resubmission
for their Herceptin biosimilar in the same year. With increasing number of approved products,
the oncology biosimilars market is expected to witness significant growth in the region over the
forecast period.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1305
Key players operating in the global oncology biosimilars market include Amgen Inc., Allergan,
Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc.,
Celltrion Healthcare, Novartis International AG, Biogen Idec, Inc., and Biocon Limited.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com